Objective To investigate the effect of dagliazine on the levels of CXC chemokine ligand 16 (CXCL16), stromal cell-derived factor-1 (SDF-1) and cyclophilin A (CypA) in patients with heart failure with reduced ejection fraction (HFrEF).
Methods A total of 156 HFrEF patients were divided into intervention group and control group according to different intervention plans, with 78 cases in each group. The control group was treated with conventional standardized drug intervention therapy, while the intervention group was treated with dagliazine on the basis of the control group. The total effective rate was compared between the two groups; the changes of CXCL16, SDF-1 and CypA levels before and after treatment were compared between the two groups; the Spearman correlation coefficient was used to analyze the correlations of CXCL16, SDF-1 and CypA with clinical efficacy; the levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C reactive protein (hs-CRP), cardiac troponin I (cTnI) and tumor necrosis factor-α (TNF-α) before and after treatment were compared between the two groups; the changes of ventricular remodeling indexes left ventricular end-diastolic diameter (LVEDd), left ventricular end-systolic diameter (LVESd), left ventricular ejection fraction (LVEF)before and after treatment were compared between the two groups; the Pearson correlation coefficient was used to analyze the correlations of CXCL16, SDF-1 and CypA with ventricular remodeling indexes.
Results The total effective rate of the intervention group was 89.74%, which was significantly higher than 73.08% of the control group (P < 0.05). After treatment, the levels of CXCL16 and CypA in both groups were significantly lower than those before treatment, while the SDF-1 level was significantly higher than that before treatment, and the levels of CXCL16 and CypA in the intervention group were significantly lower than those in the control group, while the SDF-1 level was significantly higher than that in the control group (P < 0.05). Spearman correlation coefficient analysis showed that CXCL16 and CypA levels were significantly positively correlated with clinical efficacy (P < 0.05), while SDF-1 level was significantly negatively correlated with clinical efficacy (P < 0.05). After treatment, the levels of NT-proBNP, hs-CRP, cTnI and TNF-α in both groups decreased significantly, and the levels of these indexes in the intervention group were significantly lower than those in the control group (P < 0.05). After treatment, the LVEDd and LVESd in both groups were significantly lower than those before treatment, while the LVEF was significantly higher than that before treatment, and the LVEDd in the intervention group was significantly lower than that in the control group, while the LVEF was significantly higher than that in the control group (P < 0.05). Pearson correlation coefficient analysis showed that CXCL16, SDF-1 and CypA were significantly correlated with LVEF and LVEDd (P < 0.05).
Conclusion Dagliazine is effective in the treatment of patients with HFrEF, which can increase the levels of CXCL16, SDF-1, CypA and cardiac remodeling indexes, and improve the patient's quality of life.
DownLoad: